Sponsored Links
CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln
(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)
July 30 (Reuters) - Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
Cubist said it would buy all outstanding shares of Optimer for a total of $15.75 per share in cash, including contingency payments. The offer represents a premium of 18 percent on Tuesday's closing price.
Cubist said it would pay a total of $15.50 per share for Trius, including contingency payments. The offer represents a premium of 32 percent to the stock's closing price on Tuesday. (Reporting By Vrinda Manocha in Bangalore; Editing by Maju Samuel)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints



Follow Reuters